TY - JOUR
T1 - The human lymph node microenvironment unilaterally regulates T cell activation and differentiation
AU - Knoblich, Konstantin
AU - Cruz Migoni, Sara
AU - Siew, Susan
AU - Jinks, Elizabeth
AU - Kaul, Baksho
AU - Jeffery, Hannah
AU - Baker, Alfie
AU - Suliman, Muath
AU - Vrzalikova, Katerina
AU - Mehanna, Hisham
AU - Murray, Paul
AU - Barone, Francesca
AU - Newsome, Philip
AU - Hirschfield, Gideon
AU - Kelly, Deirdre
AU - Oo, Ye Htun
AU - Lee, Steven
AU - Parekkadan, Biju
AU - Turley, Shannon
AU - Fletcher, Anne
PY - 2018/9/4
Y1 - 2018/9/4
N2 - The microenvironment of lymphoid organs can aid healthy immune function through provision of both structural and molecular support. In mice, fibroblastic reticular cells (FRCs) create an essential T cell support structure within lymph nodes, while human FRCs are largely unstudied. Here, we show that FRCs create a regulatory checkpoint in human peripheral T cell activation through four mechanisms simultaneously utilised. Human tonsil and lymph node-derived FRCs constrained the proliferation of both naïve and pre-activated T cells, skewing their differentiation away from a central memory T cell phenotype. FRCs acted unilaterally without requiring T cell feedback, imposing suppression via indoleamine-2,3-dioxygenase, adenosine 2a Receptor, prostaglandin E2, and TGFRI. Each mechanistic pathway was druggable, and a cocktail of inhibitors, targeting all four mechanisms, entirely reversed the suppressive effect of FRCs. T cells were not permanently anergized by FRCs, and studies using chimeric antigen receptor (CAR) T cells showed that immunotherapeutic T cells retained effector functions in the presence of FRCs. Since mice were not suitable as a proof-of-concept model, we instead developed a novel human tissue-based in situ assay. Human T cells stimulated using standard methods within fresh tonsil slices did not proliferate except in the presence of inhibitors described above. Collectively, we define a four-part molecular mechanism by which FRCs regulate the T cell response to strongly activating events in secondary lymphoid organs, while permitting activated and CAR T cells to utilise effector functions. Our results define four feasible strategies, used alone or in combinations, to boost primary T cell responses to infection or cancer by pharmacologically targeting FRCs.
AB - The microenvironment of lymphoid organs can aid healthy immune function through provision of both structural and molecular support. In mice, fibroblastic reticular cells (FRCs) create an essential T cell support structure within lymph nodes, while human FRCs are largely unstudied. Here, we show that FRCs create a regulatory checkpoint in human peripheral T cell activation through four mechanisms simultaneously utilised. Human tonsil and lymph node-derived FRCs constrained the proliferation of both naïve and pre-activated T cells, skewing their differentiation away from a central memory T cell phenotype. FRCs acted unilaterally without requiring T cell feedback, imposing suppression via indoleamine-2,3-dioxygenase, adenosine 2a Receptor, prostaglandin E2, and TGFRI. Each mechanistic pathway was druggable, and a cocktail of inhibitors, targeting all four mechanisms, entirely reversed the suppressive effect of FRCs. T cells were not permanently anergized by FRCs, and studies using chimeric antigen receptor (CAR) T cells showed that immunotherapeutic T cells retained effector functions in the presence of FRCs. Since mice were not suitable as a proof-of-concept model, we instead developed a novel human tissue-based in situ assay. Human T cells stimulated using standard methods within fresh tonsil slices did not proliferate except in the presence of inhibitors described above. Collectively, we define a four-part molecular mechanism by which FRCs regulate the T cell response to strongly activating events in secondary lymphoid organs, while permitting activated and CAR T cells to utilise effector functions. Our results define four feasible strategies, used alone or in combinations, to boost primary T cell responses to infection or cancer by pharmacologically targeting FRCs.
UR - http://europepmc.org/abstract/med/30180168
U2 - 10.1371/journal.pbio.2005046
DO - 10.1371/journal.pbio.2005046
M3 - Article
C2 - 30180168
SN - 1544-9173
VL - 16
JO - PLoS Biology
JF - PLoS Biology
IS - 9
M1 - e2005046
ER -